Display Settings:

Format

Send to:

Choose Destination
    Lancet Infect Dis. 2008 Jan;8(1):67-80. Epub 2007 Oct 31.

    The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.

    Source

    Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. sandrajbliss@yahoo.com

    Abstract

    Pneumococcal conjugate vaccines (PCVs) are a potentially useful complement to existing treatment strategies in HIV-infected children, for whom pneumococcal infections are common and serious. This Review summarises available data on the burden of pneumococcal disease and the safety and efficacy of PCVs in HIV-infected children. The data demonstrate that children with HIV have significantly increased risk of pneumococcal disease compared with uninfected children; the serotypes included in currently licensed or near-licensure conjugate vaccines include most serotypes that cause invasive pneumococcal disease (IPD) in HIV-infected children and adults; PCVs provide substantial protection against IPD and clinical pneumonia when given to HIV-infected infants; and HIV-infected adults gain an indirect benefit when children in the community are vaccinated. PCV should be considered as an important intervention for improving the lives of HIV-infected children.

    PMID:
    17974480
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk